• +1-646-491-9876
    • +91-20-67278686

    Search

    Fibrosis - Pipeline Review, H1 2017

    Fibrosis - Pipeline Review, H1 2017

    • Report Code ID: RW0001709426
    • Category Pharmaceuticals
    • No. of Pages 132
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Fibrosis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis - Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.

    Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 30 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

    Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Fibrosis - Overview 8
    Fibrosis - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Fibrosis - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Fibrosis - Companies Involved in Therapeutics Development 29
    Acceleron Pharma Inc 29
    Aelis Farma SAS 29
    Allakos Inc 30
    Anima Biotech Ltd 30
    Bristol-Myers Squibb Company 31
    Calypso Biotech SA 31
    Complexa Inc 32
    Encycle Therapeutics Inc 32
    F. Hoffmann-La Roche Ltd 33
    Five Prime Therapeutics Inc 33
    Genfit SA 34
    GlycoMimetics Inc 34
    Hanmi Pharmaceuticals Co Ltd 35
    iBio Inc 35
    Immunomet Therapeutics Inc 36
    Inception Sciences Inc 36
    Insmed Inc 37
    Inventiva 37
    Ironwood Pharmaceuticals Inc 38
    Isarna Therapeutics GmbH 38
    Lycera Corp 39
    Neumedicines Inc 39
    Novartis AG 40
    Palatin Technologies Inc 40
    Ribomic Inc 41
    Scholar Rock Inc 41
    SciFluor Life Sciences LLC 42
    SK Chemicals Co Ltd 42
    UCB SA 43
    VivaCell Biotechnology Espana SL 43
    Fibrosis - Drug Profiles 44
    ACE-2798 - Drug Profile 44
    AEF-0118 - Drug Profile 45
    AK-002 - Drug Profile 46
    Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile 48
    CALY-001 - Drug Profile 49
    CWHM-12 - Drug Profile 50
    elafibranor - Drug Profile 51
    G-XXX - Drug Profile 60
    IB-DMD - Drug Profile 61
    IBIOCFB-03 - Drug Profile 62
    IM-156 - Drug Profile 64
    INS-1007 - Drug Profile 65
    ISTH-1106 - Drug Profile 66
    IW-1701 - Drug Profile 67
    IW-1973 - Drug Profile 68
    LYC-53976 - Drug Profile 70
    Monoclonal Antibodies for Fibrosis - Drug Profile 71
    Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile 72
    Monoclonal Antibody 2 for Fibrosis - Drug Profile 73
    Monoclonal Antibody for Fibrotic Scar - Drug Profile 74
    Monoclonal Antibody to Activate BMP7 for Fibrosis - Drug Profile 75
    NCE-401 - Drug Profile 76
    Neumomir - Drug Profile 77
    NMIL-121 - Drug Profile 78
    OCX-063 - Drug Profile 82
    PAT-048 - Drug Profile 83
    PL-5028 - Drug Profile 84
    PRI-724 - Drug Profile 85
    Proteins for Central Nervous System Disorders and Fibrosis - Drug Profile 87
    RBM-003 - Drug Profile 88
    RBM-007 - Drug Profile 89
    Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile 90
    Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 91
    RG-6125 - Drug Profile 92
    Small Molecule for Fibrosis - Drug Profile 94
    Small Molecule for Fibrosis - Drug Profile 95
    Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 96
    Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile 97
    Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile 98
    Small Molecules for Fibrosis - Drug Profile 99
    Small Molecules for Fibrosis - Drug Profile 100
    Small Molecules for Fibrosis - Drug Profile 101
    Small Molecules for Fibrosis - Drug Profile 102
    Small Molecules for Fibrosis - Drug Profile 103
    Small Molecules for Fibrosis - Drug Profile 104
    Small Molecules for Fibrosis and Inflammatory Diseases - Drug Profile 105
    Small Molecules for Fibrosis and Oncology - Drug Profile 106
    Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 107
    Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile 108
    Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 109
    Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology - Drug Profile 110
    Small Molecules to Inhibit SphK1 for Autoimmune Disorders, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile 111
    SRI-31277 - Drug Profile 112
    ST-2001 - Drug Profile 113
    Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology - Drug Profile 114
    VCE-0048 - Drug Profile 115
    X-165 - Drug Profile 116
    XOMA-089 - Drug Profile 117
    Fibrosis - Dormant Projects 118
    Fibrosis - Product Development Milestones 120
    Featured News & Press Releases 120
    Appendix 127
    Methodology 127
    Coverage 127
    Secondary Research 127
    Primary Research 127
    Expert Panel Validation 127
    Contact Us 127
    Disclaimer 128

    List of Tables

    Number of Products under Development for Fibrosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Fibrosis - Pipeline by Acceleron Pharma Inc, H1 2017
    Fibrosis - Pipeline by Aelis Farma SAS, H1 2017
    Fibrosis - Pipeline by Allakos Inc, H1 2017
    Fibrosis - Pipeline by Anima Biotech Ltd, H1 2017
    Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Fibrosis - Pipeline by Calypso Biotech SA, H1 2017
    Fibrosis - Pipeline by Complexa Inc, H1 2017
    Fibrosis - Pipeline by Encycle Therapeutics Inc, H1 2017
    Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Fibrosis - Pipeline by Five Prime Therapeutics Inc, H1 2017
    Fibrosis - Pipeline by Genfit SA, H1 2017
    Fibrosis - Pipeline by GlycoMimetics Inc, H1 2017
    Fibrosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Fibrosis - Pipeline by iBio Inc, H1 2017
    Fibrosis - Pipeline by Immunomet Therapeutics Inc, H1 2017
    Fibrosis - Pipeline by Inception Sciences Inc, H1 2017
    Fibrosis - Pipeline by Insmed Inc, H1 2017
    Fibrosis - Pipeline by Inventiva, H1 2017
    Fibrosis - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
    Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017
    Fibrosis - Pipeline by Lycera Corp, H1 2017
    Fibrosis - Pipeline by Neumedicines Inc, H1 2017
    Fibrosis - Pipeline by Novartis AG, H1 2017
    Fibrosis - Pipeline by Palatin Technologies Inc, H1 2017
    Fibrosis - Pipeline by Ribomic Inc, H1 2017
    Fibrosis - Pipeline by Scholar Rock Inc, H1 2017
    Fibrosis - Pipeline by SciFluor Life Sciences LLC, H1 2017
    Fibrosis - Pipeline by SK Chemicals Co Ltd, H1 2017
    Fibrosis - Pipeline by UCB SA, H1 2017
    Fibrosis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
    Fibrosis - Dormant Projects, H1 2017
    Fibrosis - Dormant Projects, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development for Fibrosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Acceleron Pharma Inc
    Aelis Farma SAS
    Allakos Inc
    Anima Biotech Ltd
    Bristol-Myers Squibb Company
    Calypso Biotech SA
    Complexa Inc
    Encycle Therapeutics Inc
    F. Hoffmann-La Roche Ltd
    Five Prime Therapeutics Inc
    Genfit SA
    GlycoMimetics Inc
    Hanmi Pharmaceuticals Co Ltd
    iBio Inc
    Immunomet Therapeutics Inc
    Inception Sciences Inc
    Insmed Inc
    Inventiva
    Ironwood Pharmaceuticals Inc
    Isarna Therapeutics GmbH
    Lycera Corp
    Neumedicines Inc
    Novartis AG
    Palatin Technologies Inc
    Ribomic Inc
    Scholar Rock Inc
    SciFluor Life Sciences LLC
    SK Chemicals Co Ltd
    UCB SA
    VivaCell Biotechnology Espana SL

    Request for Sample

    Report Url http://www.reportsweb.com//fibrosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//fibrosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//fibrosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments